ArticleBMC gastroenterology2025

Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn's disease who develop secondary loss of response to infliximab.

Lin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.